Transplanted reprogrammed skin cells repair stroke-damaged rat brains
Skin cells reprogrammed into nerves and transplanted into the stroke-damaged rat brains formed functional connections that restored mobility and touch sensation.
List view / Grid view
Skin cells reprogrammed into nerves and transplanted into the stroke-damaged rat brains formed functional connections that restored mobility and touch sensation.
Using dye-loaded nanoparticles which can heat up with near-infrared light, researchers have been able to image and treat endometriosis in animal models.
Collaborators have shown that the broad spectrum oral antiviral EIDD-2801 could be a potential prophylactic or therapeutic for COVID-19 and other coronaviruses.
Ursolic acid was shown to halt the progression of chronic multiple sclerosis (MS) and reverse the damage already caused in a mouse model of the disease.
Two companies, Neurimmune and Ethris, will leverage their technologies to research, develop and produce an inhaled therapy for COVID-19.
A study has revealed that a sponge endemic to an Indonesian bay produces manzamine A, a compound which inhibits proteins in cervical cancers.
A study has demonstrated that the anti-parasitic drug ivermectin may be effective against SARS-CoV-2, the virus which causes COVID-19.
Researchers have demonstrated that cysteinase, a new drug compound, can starve pancreatic cells of cysteine supply, causing ferroptosis.
Researchers have developed two small molecules which target two components of the circadian rhythm and could be used to lengthen the body clock.
Recombinant angiotensin converting enzymes (ACE2) reduced infection and viral growth in cell cultures and organoids by acting as a decoy for SARS-CoV-2.
Drug Target Review rounds up the latest announcements regarding funding for research into COVID-19 treatments and vaccines.
Researchers have demonstrated that Nafamostat mesylate (Fusan) can inhibit SARS-CoV-2 Spike protein-initiated membrane fusion at concentrations likely achievable and safe in patients.
A molecule called BOLD-100, developed to fight cancer, has been suggested as a therapeutic to combat the COVID-19 coronavirus due to its antiviral properties.
A new compound, called FL118, was effective at combatting multiple myeloma in advanced stages of the condition in patient samples as well as mice, say researchers.
Grifols will leverage their resources to develop and test convalescent plasma-derived COVID-19 therapeutics in partnership with the FDA and BARDA.